

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10656769	
	Filing Date		2003-09-05	
	First Named Inventor	Brian Varnum		
	Art Unit	1644		
	Examiner Name	Zachary S. Skelding		
Attorney Docket Number		01-1554-F		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	01/09187	WO	A2	2001-02-08	Medarex, Inc.	whole document	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10656769
Filing Date	2003-09-05
First Named Inventor	Brian Vamum
Art Unit	1644
Examiner Name	Zachary S. Skelding
Attorney Docket Number	01-1554-F

1	Edinger et al., 2000, Characterization of epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein, J. Virol., 74(17): 7922-7935.	<input type="checkbox"/>
2	Sims John E. et al., 1993, Interleukin-1 signaling occurs exclusively via the type 1 receptor, PNAS, 90(13): 6155-6159.	<input type="checkbox"/>
3	Purified rat anti-mouse CD121a (IL receptor, type 1, p80) monoclonal antibody (no azide/ low endotoxin), Technical Data Sheet BD Pharmingen, June 2003, (2003-06), page 1.	<input type="checkbox"/>
4	Choe JY et al., 2003, Interleukin-1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J. Experimental Medicine, Tokyo, JP, 197(4): 537-542.	<input type="checkbox"/>
5		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.